Name: Natamycin
Brand: Selleck Chemicals
SKU: S1517
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.92%

99.92

Related Targets	Integrase Bacterial Antibiotics Anti-infection Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease
Other Fungal Inhibitors	Cycloheximide Tolnaftate Manogepix (E1210) Neticonazole Amorolfine HCl Thimerosal Isavuconazole Allicin Neticonazole Hydrochloride Juglone

Solubility

In vitro
Batch:

DMSO : 10 mg/mL (15.02 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	665.73	Formula	C₃₃H₄₇NO₁₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	7681-93-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Pimaricin			Smiles	CC1CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC3C(O3)C=CC(=O)O1)O)O)O)C(=O)O)OC4C(C(C(C(O4)C)O)N)O

Mechanism of Action

In vitro

Natamycin binds specifically to ergosterol present in model membranes. This compound does not change the permeability of the yeast plasma membrane under conditions that growth is blocked. It blocks the fusion of isolated vacuoles without compromising the barrier function of the vacuolar membrane. This chemical perturbs the cellular vacuole morphology, causing the formation of many more small vacuolar structures in yeast cells. It inhibits the priming stage of vacuole fusion. It shows low MIC against the dematiaceous fungi, Curvularia species. It is complexed with gamma-cyclodextrin (NT-gamma CyD) to increase the solubility and stability of NT in aqueous solutions and reduce the side effects of the drug without decreasing antimycotic activity. MIC90 of this compound alone and this chemical-gamma CyD complexes are below 0.0313 mg/mL, suggesting that complexation with gamma CyD has effectively increased the antimycotic activity of it, thus indicating the clinical usefulness of it-gamma CyD complexes.

References

[1] https://pubmed.ncbi.nlm.nih.gov/18165687/
[2] https://pubmed.ncbi.nlm.nih.gov/20385867/
[3] https://pubmed.ncbi.nlm.nih.gov/22011503/

[4] https://pubmed.ncbi.nlm.nih.gov/18775980/
[5] https://pubmed.ncbi.nlm.nih.gov/18288724/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00997035	Completed	Corneal Ulcer\|Eye Infections Fungal	University of California San Francisco\|Aravind Eye Hospitals India\|Dartmouth-Hitchcock Medical Center\|Lumbini Eye Institute and Hospital\|Bharatpur Eye Hospital\|National Eye Institute (NEI)	May 2010	Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Natamycin Fungal inhibitor

Chemical Structure

Molecular Weight: 665.73